Bioventix Plc - Director Dealing
27 October 2022 - 5:00PM
PR Newswire (US)
Bioventix plc
(“Bioventix” or “the Company”)
Director
Dealing
Bioventix plc (BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for applications in clinical diagnostics, announces that
it has been notified that Bruce
Hiscock, Chief Financial Officer of the Company, completed
the following dealings in the Company’s ordinary shares of
5 pence in the Company ("Ordinary
Shares"):
- the transfer, via sale and purchase, of 204 Ordinary Shares
into his ISA. Mr Hiscock sold 204 Ordinary Shares at a price of
£33.41 from an account in his own name and bought 204 Ordinary
Shares at a price of £34.00 to be held in his ISA; and
- the additional purchase of 276 Ordinary Shares at a price of
£34.00 into his ISA.
Following these transactions, Mr Hiscock’s total beneficial
interest in the Company is now 700 Ordinary Shares, representing
approximately 0.01 per cent. of the Company’s total issued share
capital.
For further information please
contact:
Bioventix plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728
001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks/Abigail Kelly
Alice Lane |
Corporate Finance
ECM |
Tel: 020 7220
0500 |
| 1. |
Details of the person
discharging managerial responsibilities / person closely
associated |
| a) |
Name |
Bruce Hiscock |
| 2. |
Reason for the
Notification |
| a) |
Position/status |
Chief Financial Officer |
| b) |
Initial notification/Amendment |
Initial notification |
| 3. |
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor |
| a) |
Name |
Bioventix plc |
| b) |
LEI |
213800225MHX7LZQY108 |
| 4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the
Financial instrument, type of instrument |
Ordinary Shares |
| Identification code |
GB00B4QVDF07 |
| b) |
Nature of the transaction |
Sale of Ordinary Shares |
| c) |
Price(s) and volume(s) |
| Volume(s) |
Prices (pence) |
| 204 |
3,341 |
|
| d) |
Aggregated
information:
·Aggregated volume
·Price |
Sale of 204 Ordinary Shares at a
price of 3,341p per Ordinary Share |
| e) |
Date of the transaction |
26 October 2022 |
| f) |
Place of the transaction |
London Stock Exchange, AIM Market
(XLON) |
| 1. |
Details of the person
discharging managerial responsibilities / person closely
associated |
| a) |
Name |
Bruce Hiscock |
| 2. |
Reason for the
Notification |
| a) |
Position/status |
Chief Financial Officer |
| b) |
Initial notification/Amendment |
Initial notification |
| 3. |
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor |
| a) |
Name |
Bioventix plc |
| b) |
LEI |
213800225MHX7LZQY108 |
| 4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the
Financial instrument, type of instrument |
Ordinary Shares |
| Identification code |
GB00B4QVDF07 |
| b) |
Nature of the transaction |
Purchase of Ordinary Shares |
| c) |
Price(s) and volume(s) |
| Volume(s) |
Prices (pence) |
| 480 |
3,400 |
|
| d) |
Aggregated
information:
·Aggregated volume
·Price |
Purchase of 480
Ordinary Shares at a price of 3,400p per Ordinary Share |
| e) |
Date of the transaction |
26 October 2022 |
| f) |
Place of the transaction |
London Stock Exchange, AIM Market
(XLON) |
Copyright r 26 PR Newswire
Bioventix (LSE:BVXP)
Historical Stock Chart
From Jan 2025 to Feb 2025
Bioventix (LSE:BVXP)
Historical Stock Chart
From Feb 2024 to Feb 2025
